Adenoid Cystic carcinoma of minor salivary glands (AdCCmSG): a multidisciplinary update

被引:1
作者
Romano, Rebecca [1 ]
De Felice, Francesca [2 ]
Ferri, Andrea [3 ]
Della Monaca, Marco [4 ,5 ]
Maroldi, Roberto [6 ]
Licitra, Lisa [1 ,7 ]
Locati, Laura Deborah [8 ,9 ]
Alfieri, Salvatore [1 ]
机构
[1] Fdn IRCCS Ist Nazl Tumori, Head & Neck Med Oncol Dept, Via Giacomo Venezian 1, I-20133 Milan, MI, Italy
[2] Sapienza Univ Rome, Dept Radiotherapy, Policlin Umberto I, Rome, Italy
[3] Univ Hosp Parma, Head & Neck Dept, Maxillofacial Surg Div, Viale Antonio Gramsci 14, I-43126 Parma, PR, Italy
[4] Sapienza Univ Rome, Dept Oral & Maxillofacial Sci, Rome, Italy
[5] Policlin Umberto 1, Oncol & Reconstruct Maxillofacial Surg Unit, Rome, Italy
[6] Univ Brescia, Dept Med & Surg Specialties, Div Radiol, Radiol Sci & Publ Hlth, Brescia, Italy
[7] Univ Milan, Milan, Italy
[8] Ist Ric & Cura Carattere Sci IRCCS, Ist Clin Sci ICS Maugeri, Translat Oncol Unit, Pavia, Italy
[9] Univ Pavia, Dept Internal Med & Med Therapy, Pavia, Italy
关键词
minor salivary gland cancer (mSGC); Adenoid Cystic carcinoma (AdCC); histotype; head and neck; radiation therapy; surgery; targeted therapy; LYMPH-NODE METASTASIS; POSTOPERATIVE RADIATION-THERAPY; SQUAMOUS-CELL CARCINOMA; SYSTEMIC THERAPY; NECK DISSECTION; ORAL-CAVITY; PHASE-II; HEAD; RADIOTHERAPY; TUMORS;
D O I
10.1080/14737140.2024.2357806
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
IntroductionAdenoid cystic carcinoma of minor salivary glands (AdCCmSG) represents a 'rarity in the rarity,' posing a clinical challenge in lack of standardized, evidence-based recommendations. At present, AdCCmSG management is mostly translated from major salivary gland cancers (MSGCs). Ideally, AdCCmSG diagnostic-therapeutic workup should be discussed and carried out within a multidisciplinary, high-expertise setting, including pathologists, surgeons, radiation oncologists and medical oncologists.Areas CoveredThe present review provides an overview of epidemiology and pathologic classification. Moreover, the most recent, clinically relevant updates in the treatment of AdCCmSG (Pubmed searches, specific guidelines) are critically discussed, aiming to a better understanding of this rare pathologic entity, potentially optimizing the care process, and offering a starting point for reflection on future therapeutic developments.Expert OpinionThe management of rare cancers is often hindered by limited data and clinical trials, lack of evidence-based guidelines, and hardly represented disease heterogeneity, which cannot be successfully tackled with a 'one-size-fits-all' approach. Our goal is to address these potential pitfalls, providing an easy-to-use, updated, multidisciplinary collection of expert opinions concerning AdCCmSG management as of today's clinical practice. We will also cover the most promising future perspectives, based on the potential therapeutic targets highlighted within AdCCmSG's molecular background.
引用
收藏
页码:567 / 580
页数:14
相关论文
共 100 条
[31]   Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma [J].
Even, C. ;
Lassen, U. ;
Merchan, J. ;
Le Tourneau, C. ;
Soria, J-C ;
Ferte, C. ;
Ricci, F. ;
Diener, J. T. ;
Yuen, E. ;
Smith, C. ;
Oakley, G. J., III ;
Benhadji, K. A. ;
Massard, Christophe .
INVESTIGATIONAL NEW DRUGS, 2020, 38 (02) :402-409
[32]   Current opinions on diagnosis and treatment of adenoid cystic carcinoma [J].
Fang, Yan ;
Peng, Zhouying ;
Wang, Yumin ;
Gao, Kelei ;
Liu, Yalan ;
Fan, Ruohao ;
Zhang, Hua ;
Xie, Zhihai ;
Jiang, Weihong .
ORAL ONCOLOGY, 2022, 130
[33]   The gamma secretase inhibitor AL101 combined with other drugs for dual targeting of Notch dysregulated tumors [J].
Ferrarotto, R. ;
Rauch, R. ;
Leibovich, T. ;
Shitrit, A. ;
Solomon, O. ;
Herz, E. ;
Walker, R. M. ;
Ho, A. L. ;
Kaye, J. .
ANNALS OF ONCOLOGY, 2021, 32 :S1222-S1222
[34]   A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors [J].
Ferrarotto, R. ;
Eckhardt, G. ;
Patnaik, A. ;
LoRusso, P. ;
Faoro, L. ;
Heymach, J. V. ;
Kapoun, A. M. ;
Xu, L. ;
Munster, P. .
ANNALS OF ONCOLOGY, 2018, 29 (07) :1561-1568
[35]   Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma [J].
Ferrarotto, Renata ;
Sousa, Luana G. ;
Feng, Lei ;
Mott, Frank ;
Blumenschein, George ;
Altan, Mehmet ;
Bell, Diana ;
Bonini, Flavia ;
Li, Kaiyi ;
Marques-Piubelli, Mario L. ;
Dal Lago, Eduardo A. ;
Johnson, Jason J. ;
Mitani, Yoshitsugu ;
Godoy, Myrna ;
Lee, Anna ;
Kupferman, Michael ;
Hanna, Ehab ;
Glisson, Bonnie S. ;
Elamin, Yasir ;
El-Naggar, Adel .
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (15) :2843-+
[36]   Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets [J].
Ferrarotto, Renata ;
Mitani, Yoshitsugu ;
McGrail, Daniel J. ;
Li, Kaiyi ;
Karpinets, Tatiana, V ;
Bell, Diana ;
Frank, Steven J. ;
Song, Xingzhi ;
Kupferman, Michael E. ;
Liu, Bin ;
Lee, J. Jack ;
Glisson, Bonnie S. ;
Zhang, Jianhua ;
Aster, Jon C. ;
Lin, Shiaw-Yih ;
Futreal, P. Andrew ;
Heymach, John, V ;
El-Naggar, Adel K. .
CLINICAL CANCER RESEARCH, 2021, 27 (03) :852-864
[37]   The spectral geometry of de Sitter space in asymptotic safety [J].
Ferrero, Renata ;
Reuter, Martin .
JOURNAL OF HIGH ENERGY PHYSICS, 2022, 2022 (08)
[38]   Staging and follow-up of high-grade malignant salivary gland tumours: The role of traditional versus functional imaging approaches - A review [J].
Freling, Nicole ;
Crippa, Flavio ;
Maroldi, Roberto .
ORAL ONCOLOGY, 2016, 60 :157-166
[39]  
GARDEN AS, 1994, CANCER, V73, P2563, DOI 10.1002/1097-0142(19940515)73:10<2563::AID-CNCR2820731018>3.0.CO
[40]  
2-X